PharmaResearch Co., Ltd. (KOSDAQ:214450)

PharmaResearch Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 18, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	5,890,930	2,727,283	1,116,952	697,316	818,025	552,155
Market Cap Growth	235.14%	144.17%	60.18%	-14.76%	48.15%	60.62%
Enterprise Value	5,673,455	2,575,782	990,868	612,568	761,136	536,011
Last Close Price	567000.00	262500.00	109041.14	68996.50	80178.04	55527.18
PE Ratio	53.24	29.63	14.59	17.18	17.52	16.85
Forward PE	34.68	22.06	12.55	10.92	14.49	15.04
PS Ratio	15.02	7.79	4.28	3.58	5.31	5.08
PB Ratio	9.90	4.78	2.42	1.88	2.49	2.09
P/TBV Ratio	11.11	5.38	2.77	2.27	3.10	2.67
P/FCF Ratio	60.23	26.82	21.12	16.55	18.32	-
P/OCF Ratio	42.41	19.75	17.20	11.74	12.53	17.05
EV/Sales Ratio	14.46	7.36	3.80	3.15	4.94	4.93
EV/EBITDA Ratio	35.82	18.44	9.50	8.01	12.27	12.83
EV/EBIT Ratio	39.37	20.43	10.74	9.29	14.50	16.04
EV/FCF Ratio	58.01	25.33	18.74	14.53	17.05	-
Debt / Equity Ratio	0.35	0.37	0.07	0.18	0.20	0.12
Debt / EBITDA Ratio	1.33	1.49	0.33	0.87	1.06	0.78
Debt / FCF Ratio	2.15	2.05	0.65	1.58	1.47	-
Asset Turnover	0.53	0.50	0.52	0.43	0.41	0.37
Inventory Turnover	2.03	1.84	1.90	2.55	2.40	2.07
Quick Ratio	5.64	5.84	2.96	4.04	3.86	2.87
Current Ratio	6.45	6.75	3.89	4.56	4.31	3.55
Return on Equity (ROE)	20.00%	17.23%	18.53%	12.41%	15.80%	13.17%
Return on Assets (ROA)	12.27%	11.33%	11.38%	9.10%	8.78%	7.08%
Return on Capital (ROIC)	13.66%	12.35%	12.34%	9.90%	9.50%	7.65%
Return on Capital Employed (ROCE)	18.00%	16.30%	19.70%	15.60%	13.80%	11.80%
Earnings Yield	1.88%	3.38%	6.85%	5.82%	5.71%	5.94%
FCF Yield	1.66%	3.73%	4.74%	6.04%	5.46%	-0.43%
Dividend Yield	0.19%	0.42%	0.87%	0.96%	0.75%	0.90%
Payout Ratio	9.09%	10.96%	9.84%	15.56%	10.77%	9.04%
Buyback Yield / Dilution	0.09%	2.50%	-5.85%	0.76%	-5.74%	-0.73%
Total Shareholder Return	0.29%	2.92%	-4.97%	1.72%	-4.99%	0.17%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.